SYN-X develops Alzheimer's screening test
This article was originally published in Clinica
SYN-X Pharma has introduced a rapid in vitro diagnostic aid that can screen for early signs of Alzheimer's disease from just a few drops of blood. The Nexus Dx assay, intended for use as a point-of-care test in a doctor's or specialist's office, could potentially lead to the initiation of drug treatment, says the Ontario, Canada firm. Drug therapy must begin early in order to slow or minimise the extent of neurological damage associated with the disease. More than 22 million individuals globally will suffer from Alzheimer's disease by 2025, says SYN-X.